<?xml version="1.0" encoding="UTF-8"?>
<p>In the United Kingdom, the Health Research Authorities (HRA) published a response to the pandemic advising clinical trials to evaluate the risk-benefit of their trial in the broader context of the impact of COVID-19 on National Health Service (NHS) staffing, restriction of movement and government advice [
 <xref rid="REF2" ref-type="bibr">2</xref>]. The National Institute for Health Research (NIHR) strategic response stated that all non-COVID-19 related trial set-up activity would be temporarily suspended, and trials in the recruitment stage halted on a case-by-case basis to ensure the prioritisation of COVID-19 studies and to enable the redeployment of clinical staff to frontline care [
 <xref rid="REF3" ref-type="bibr">3</xref>]. Since then, the Medicines and Healthcare products Regulatory Agency (MHRA) have issued pragmatic guidance on how to manage clinical trials during the pandemic, including practical guidance on the safe delivery of Investigational Medical Products (IMPs) to participants in self-isolation, remote monitoring of trials, protocol deviations and ensuring timely and appropriate measures for pharmacovigilance [
 <xref rid="REF4" ref-type="bibr">4</xref>].
</p>
